Skip to main content

Table 5 Threshold values for selected meta-model inputs where the net monetary benefit (i.e., overall value quantified as monetized QALYs at $100,000/QALY minus costs) of the CMR strategy is equal to a competing strategy (Ge 2020 value represents base-case model input value)

From: Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease

Variable

Base-case values in meta-model

Calculated threshold values to be equivalent to CMR strategy

Ge 2020 value [13]

Ge source(s)

No imaginga

CCTAa

SPECTa

XCAa

CMR sensitivity

0.89

Knuuti et al. [8]

0.37 (42%)

0.68 (76%)

0.55 (62%)

0.34 (38%)

CMR specificity

0.87

Knuuti et al. [8]

0.37 (43%)

0.66 (76%)

0.55 (63%)

0.34 (39%)

CMR cost

$807

CMS

$2420 (300%)

$1465 (182%)

$1840 (228%)

$2522 (313%)

Age (years)

62.5

Kwong et al. [46]

None

None

None

None

Prevalence of CAD

32.4%

Kwong et al. [46]

15% (47%)

None

None

66% (204%)

  1. CAD coronary artery disease, CCTA coronary computed tomographic angiography, CMR cardiovascular magnetic resonance, SPECT single-photon emission computed tomography, QALY quality-adjusted life year, XCA x-ray coronary angiography
  2. aThreshold value for this model input parameter that sets net monetary benefit (i.e., value) of CMR strategy equal to this strategy. “None” indicates not threshold value result exists for this parameter (i.e., CMR strategy is optimal over full range of possible values holding all other model inputs constant). Parentheses indicate percent of base-case value used be Ge et al. [13]